CardioGenesis Laser Therapies for Angina and Heart Disease Patients 4 23 03 Q 1 03 Page 4
CARDIOGENESIS CORPORATION REPORTS 2003 FIRST QUARTER RESULTS
PAGE 4-4-4
CARDIOGENESIS CORPORATION
CONDENSED AND CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended
March 31,
2003
2002
Net revenues
$ 3,422
$ 3,158
Cost of revenues
622
826
Gross profit
2,800
2,332
Operating expenses:
Research and development
383
206
Sales, general and administrative
2,298
3,372
Total operating expenses
2,681
3,578
Income (loss) from operations
119
(1,246)
Non-operating income , net
2
7
Net income (loss)
$ 121
$ (1,239)
Net income (loss) per share -
basic and diluted
$ 0.00
$ (0.03)
Shares used in
per share computations -
Basic
37,121
36,507
Diluted
37,145
36,507
MORE-MORE-MORE
